1Bandelow, B, Zohar, J, Hollander, E, Kasper, S, Moller, HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008; 9(4): 248–312.
2Baldwin, DS, Anderson, IM, Nutt, DJ, Allgulander, C, Bandelow, B, den Boer, JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014; 28(5): 403–39.
3National Institute for Health and Care Excellence (NICE). Anxiety: Management of Anxiety (Panic Disorder, with or without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care. The British Psychological Society and The Royal College of Psychiatrists, 2011.
4Bandelow, B, Reitt, M, Rover, C, Michaelis, S, Gorlich, Y, Wedekind, D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol 2015; 30(4): 183–92.
5National Institute for Health and Care Excellence (NICE). Anxiety (amended): Management of Anxiety (Panic Disorder, with or without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care. NICE, 2007.
6National Institute for Health and Care Excellence (NICE). Social Anxiety Disorder: Recognition, Assessment and Treatment (Full Guideline). The British Psychological Society and The Royal College of Psychiatrists, 2013.
7Durham, RC, Chambers, JA, Power, KG, Sharp, DM, Macdonald, RR, Major, KA, et al. Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland. Health Technol Assess 2005; 9(42): 1–174.
8Donovan, MR, Glue, P, Kolluri, S, Emir, B. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders – a meta-analysis. J Affect Disord 2010; 123(1–3): 9–16.
9Marks, IM, Swinson, RP, Basoglu, M, Kuch, K, Noshirvani, H, O'Sullivan, G, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry 1993; 162: 776–87.
10Loerch, B, Graf-Morgenstern, M, Hautzinger, M, Schlegel, S, Hain, C, Sandmann, J, et al. Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br J Psychiatry 1999; 174: 205–12.
11Barlow, DH, Gorman, JM, Shear, MK, Woods, SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000; 283(19): 2529–36.
12Cohen, SD, Monteiro, W, Marks, IM. Two-year follow-up of agoraphobics after exposure and imipramine. Br J Psychiatry 1984; 144(3): 276–81.
13Mavissakalian, M, Michelson, L, Dealy, RS. Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice. Br J Psychiatry 1983; 143: 348–55.
14Clark, DM, Ehlers, A, McManus, F, Hackmann, A, Fennell, M, Campbell, H, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003; 71(6): 1058–67.
15Nordahl, HM, Vogel, PA, Morken, G, Stiles, TC, Sandvik, P, Wells, A. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychother Psychosom 2016; 85(6): 346–56.
16Liebowitz, MR, Heimberg, RG, Schneier, FR, Hope, DA, Davies, S, Holt, CS, et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depress Anxiety 1999; 10(3): 89–98.
17Haug, TT, Blomhoff, S, Hellstrom, K, Holme, I, Humble, M, Madsbu, HP, et al. Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial. Br J Psychiatry 2003; 182: 312–8.
18Patterson, B, Boyle, MH, Kivlenieks, M, Van Ameringen, M. The use of waitlists as control conditions in anxiety disorders research. J Psychiatr Res 2016; 83: 112–20.
20Leichsenring, F, Salzer, S, Beutel, ME, Herpertz, S, Hiller, W, Hoyer, J, et al. Long-term outcome of psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder. Am J Psychiatry 2014; 171: 1074–82.
21Hamilton, M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32(1): 50–5.
22Liebowitz, MR. Social phobia. Mod Probl Pharmacopsychiatry 1987; 22: 141–73.
23Dunlap, WP, Cortina, JM, Vaslow, JB, Burke, MJ. Meta-analysis of experiments with matched groups or repeated measures designs. Psychol Methods 1996; 1(2): 170–7.
24Borenstein, M, Hedges, L, Higgins, J, Rothstein, H. Introduction to Meta-Analysis. Wiley, 2009.
25Little, RJ, D'Agostino, R, Cohen, ML, Dickersin, K, Emerson, SS, Farrar, JT, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012; 367(14): 1355–60.
26Ioannidis, JP, Patsopoulos, NA, Evangelou, E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007; 335(7626): 914–6.
27Higgins, JP, Thompson, SG, Deeks, JJ, Altman, DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414): 557–60.
28Moher, D, Altman, DG, Liberati, A, Tetzlaff, J. PRISMA statement. Epidemiology 2011; 22(1): 128.